HerClarityhealth
HomeDiagnosisAm I Going Crazy? Perimenopause and Your Mental Health
Diagnosis · 8 min · Updated May 19, 2026

Am I Going Crazy? Perimenopause and Your Mental Health

This is the question women in their forties whisper to their best friends and type into Google at 2 a.m. The answer is no — and the science of why you feel this way has been sitting in the research literature for two decades.

Dr. Maya Okonkwo
Reviewed by Dr. R. Chen, MD
8 min
Illustration · Eliza Park for HerClarity

Is it normal to feel like your mental health has fallen apart in perimenopause?

Yes — and the data back you up. Perimenopause is a documented window of elevated risk for depression, anxiety, and mood instability. This is not a matter of being overwhelmed by life or "not coping well." It is a measurable, biological vulnerability tied to the same hormonal shifts that change your periods and your sleep.

The largest long-term study of women in midlife, SWAN (Study of Women's Health Across the Nation), followed more than 3,000 women across the menopause transition and found that the odds of experiencing high levels of depressive symptoms were two to four times greater during the transition than in the premenopausal years.11 Women were also more likely to meet the clinical criteria for major depression during the transition than before it began.11

If you feel like something has genuinely changed — not just harder days, but a different baseline — you are probably right. That shift is real.

What does the research actually show about new depression during perimenopause?

The clearest evidence comes from women who had never experienced depression before perimenopause began.

In the Harvard Study of Moods and Cycles, researchers followed women with no prior history of depression and found that risk of new-onset major depression was approximately doubled during the menopause transition compared with the premenopausal years.22 These were women for whom depression was genuinely new — not a recurrence, not a pre-existing condition.

This matters because it directly answers the "but I've never had anxiety or depression before" response that dismisses so many women's concerns. That history of stability doesn't protect you during this window. It also means you deserve to be taken seriously, not reassured that you are fine because you used to be fine.

How does estrogen affect the brain and mood?

Estrogen is not just a reproductive hormone. It is deeply involved in how your brain works.

Estrogen modulates the activity of serotonin — the neurotransmitter most associated with mood stability — by influencing both how much is made and how efficiently it is used.33 It also supports GABA, the brain's main calming signal, and affects dopamine, which drives motivation and reward. On top of that, estrogen helps regulate the HPA axis — the body's central stress-response system — and supports neuroplasticity and the brain's use of glucose for energy.

When estrogen fluctuates erratically — as it does throughout perimenopause, sometimes spiking high before dropping, rather than simply falling steadily — all of those systems are repeatedly destabilized. The result is not a steady low mood but something more unpredictable: sudden tearfulness, rage that seems out of proportion, anxiety that arrives without an obvious trigger, a sense that you can no longer rely on your own emotional responses.

Why are some women more vulnerable than others?

One of the most important findings in this field is that the women at highest risk are not those with the lowest estrogen levels. They are the women who are most sensitive to hormonal change.

Research led by Peter Schmidt at the National Institute of Mental Health showed that mood symptoms in perimenopause track with sensitivity to estrogen fluctuation rather than with absolute hormone levels.33 This explains a pattern that many women recognize: the worst emotional turbulence often happens early in perimenopause, when hormones are swinging most unpredictably — not in postmenopause, when levels have settled at a new, lower baseline.

Women with a history of PMS, PMDD (premenstrual dysphoric disorder), or postpartum mood symptoms are particularly vulnerable to perimenopausal mood changes.33 These conditions share an underlying sensitivity to hormonal shifts — the same sensitivity that PMDD exploited monthly now operates across years. If this describes you, it is not a coincidence, and it is not a character weakness. It is a recognized neuroendocrine pattern.

How is this different from just feeling stressed or burned out?

The honest answer is that it can be hard to separate, and the causes are not mutually exclusive.

Perimenopause typically coincides with a period of life that is objectively demanding: caring for aging parents, raising teenagers, navigating a career at full stretch, sleeping poorly, and doing all of it in a culture that has not given midlife women's mental health a name or a vocabulary. These pressures are real. They amplify the biological vulnerability.

But the key marker of a hormonally driven component is the quality of what you feel. Perimenopausal mood symptoms often feel different from ordinary stress — more physical in character, less tied to actual events, more sudden in their arrival and departure. Crying for no reason. Rage at something minor. An anxiety that shows up in your body before your mind has had a chance to engage. A flatness that is not sadness exactly, just the absence of the emotional range you used to have.

If your mood has become unreliable in ways that feel new, this distinction matters — not to discourage you from addressing the life circumstances, but to make sure you also address the biology.

What should you do — and what actually helps?

The starting point is being taken seriously by a clinician who knows this territory.

NAMS and the North American Menopause Society's 2018 clinical guidelines recommend standard screening tools — the PHQ-9 for depression, the GAD-7 for anxiety — and treat perimenopausal depression with the same evidence-based tools used for depression generally, starting with antidepressants or psychotherapy.33 The addition specific to perimenopause: transdermal estradiol has evidence for preventing and treating depressive symptoms specifically in the early menopause transition, not in postmenopause.33 A twelve-month randomized controlled trial found that transdermal estradiol with intermittent micronized progesterone cut the rate of clinically significant depressive symptoms roughly in half — 17.3% on the active treatment versus 32.3% on placebo.55

For women whose depression and anxiety are tangled with poor sleep, treating the sleep is not optional — it is part of treating the mood. Night-time hot flashes that fragment sleep directly worsen mood the next day, independent of other factors.33

SSRIs and SNRIs — venlafaxine, desvenlafaxine, escitalopram, paroxetine — have the additional benefit that several of them also reduce hot flashes, offering a meaningful two-for-one when mood symptoms and vasomotor symptoms are both present.33

Cognitive behavioral therapy has strong evidence for menopausal mood and is often used alongside medication or as a standalone treatment for women who prefer not to start a drug or cannot take one.

A practical step: look for a Menopause Society Certified Practitioner at menopause.org. The provider training gap in this area is real — documented research found that fewer than 7% of US family medicine, internal medicine, and OB/GYN residents felt adequately prepared to manage menopause, and only about 31% of OB/GYN residency programs had any menopause curriculum at all.44 Finding a provider who has invested in this training makes a measurable difference.

Sources
  1. Bromberger JT, Kravitz HM, Chang YF, et al. Major depression during and after the menopausal transition: SWAN. Psychol Med. 2011;41(9):1879–1888.
  2. Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry. 2006;63(4):385–390.
  3. Maki PM, Kornstein SG, Joffe H, et al. Guidelines for the evaluation and treatment of perimenopausal depression. Menopause. 2018;25(10):1069–1085. doi:10.1097/GME.0000000000001174.
  4. Kling JM, MacLaughlin KL, Schnatz PF, et al. Menopause management knowledge in postgraduate FM, IM, and OB/GYN residents. Mayo Clin Proc. 2019;94(2):242–253. Also: Allen JT, Laks S, Zahler-Miller C, et al. Needs assessment of menopause education in US OB/GYN residency training programs. Menopause. 2023;30(10):1002–1005.
  5. Gordon JL, Rubinow DR, Eisenlohr-Moul TA, et al. Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: a RCT. JAMA Psychiatry. 2018;75(2):149–157. doi:10.1001/jamapsychiatry.2017.3998.
The Friday Briefing

What the research says this week.

One email Friday morning. Plain-English summaries, no fluff.

Free. Unsubscribe anytime.